Stockscreener 앱 받기
2.89
9.69%
-0.31
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Value Recap: What are Hess Corporations earnings expectationsMarket Trend Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Outlook: Is TOMI Environmental Solutions Inc in accumulation or distribution phase2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Stop Loss: Is Annovis Bio Inc stock a smart retirement pickJuly 2025 Market Mood & Smart Swing Trading Alerts - baoquankhu1.vn
Can Annovis Bio Inc. stock surprise with earnings upside2025 Buyback Activity & Verified Chart Pattern Signals - Улправда
What is the fair value of Annovis Bio Inc. stock nowJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - Улправда
How Annovis Bio Inc. stock reacts to oil prices2025 Biggest Moves & Daily Profit Maximizing Tips - Улправда
Will Annovis Bio Inc. stock maintain momentum in 2025Earnings Trend Report & Safe Swing Trade Setups - Улправда
Why Annovis Bio Inc. stock remains on watchlistsWeekly Gains Report & Safe Entry Zone Identification - Улправда
Will Annovis Bio Inc. stock outperform Nasdaq index2025 Trading Volume Trends & Intraday High Probability Setup Alerts - ulpravda.ru
2026 world cup match preview guide: Will Annovis Bio Inc. stock attract ESG investors2026 world cup usa national team qualification defensive leaders counter attacking group prediction tactical review - Улправда
Published on: 2026-01-06 13:56:48 - ulpravda.ru
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
New trial offers extended buntanetap access for people with Parkinson’s - Parkinson's News Today
Breakout Watch: How Annovis Bio Inc stock reacts to oil pricesOptions Play & Reliable Intraday Trade Alerts - moha.gov.vn
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
History Review: Is Annovis Bio Inc stock attractive for growth ETFsJuly 2025 Update & Breakout Confirmation Alerts - moha.gov.vn
Annovis sets investor webinar as neurodegeneration pipeline reaches inflection - MSN
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Published on: 2025-12-25 20:53:49 - moha.gov.vn
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug - MyChesCo
Annovis Sets Investor Webinar as Neurodegeneration Pipeline Reaches Inflection - MyChesCo
Inflation Data: Is Annovis Bio Inc. stock positioned for secular growthTrade Risk Summary & Verified Stock Trade Ideas - Улправда
Why analysts remain bullish on Annovis Bio Inc. stockJuly 2025 Technicals & Short-Term Swing Trade Alerts - Улправда
Is Annovis Bio Inc. stock positioned for secular growthMarket Activity Recap & AI Driven Price Predictions - Улправда
Volume Summary: Can Annovis Bio Inc. stock hold up in economic slowdownShort Setup & Technical Pattern Alert System - moha.gov.vn
What technical patterns form on Annovis Bio Inc. stock chartsTrade Entry Report & Technical Confirmation Alerts - Улправда
Why Annovis Bio Inc. stock appears on watchlistsJuly 2025 Summary & Stepwise Trade Signal Guides - DonanımHaber
Annovis Plans 36-Month Extension Study To Further Evaluate Buntanetap In Parkinson's - Nasdaq
Is Annovis Bio Inc. stock a smart buy before Fed meetingJuly 2025 Spike Watch & AI Driven Price Forecasts - DonanımHaber
Annovis Bio to launch long-term Parkinson’s drug study in January - Investing.com India
Annovis Bio to launch long-term Parkinson’s drug study in January By Investing.com - Investing.com South Africa
Annovis Bio to Launch Long-Term Open-Label Study for Buntanetap in Parkinson's Disease Patients Starting January 2026 - Quiver Quantitative
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewswire
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease - TipRanks
Will Annovis Bio Inc. stock attract ESG investorsTrade Performance Summary & Real-Time Stock Entry Alerts - Улправда
Annovis Bio Earnings Notes - Trefis
Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - Reuters
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MSN
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio director Hoffman buys $193,794 in shares By Investing.com - Investing.com UK
Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock - MarketBeat
Annovis Bio director Hoffman buys $193,794 in shares - Investing.com India
Annovis Bio (ANVS) director reports 45,000-share insider purchase at around $4 - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
Published on: 2025-12-08 04:36:17 - moha.gov.vn
Annovis Bio Inc. (ANVS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Can Annovis Bio Inc. stock deliver consistent EPS growth2025 Retail Activity & High Yield Stock Recommendations - Newser
Is Annovis Bio Inc. stock a top hedge fund pickEarnings Beat & High Conviction Buy Zone Picks - Newser
Why institutional investors increase stakes in Annovis Bio Inc. stockEarnings Performance Report & Capital Efficiency Focused Ideas - Newser
4.73%
0.92%
자본화:
|
볼륨(24시간):